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2nd Gen PCB 1st Gen PCB POBA p
Area of
Stenosis (%)
50.5 54.8 18.1% 78.2 9.8% 0.01
Neointimal
Thickness (mm)
0.85 0.2 0.86 0.4 1.35 0.2 0.01
Fibrin deposition
(0-3)
0.5 [0.3-0.7] 2.4 [2-3] 0.1# 0.01
Neointimal
maturity (0-3)
3# 1.3 [1-1.8] 3# 0.01
Medial cell loss
(0-3)
3# 1.7 [1-1.8] 3# 0.01
Endothelialization
(0-3)
3# 2.5 [2-2.6] 3# 0.01
p0.05 vs. POBA. #p0.05 vs. 1st gen PCB
Conclusions: Second generation PCB achieved similar degree of neointimal inhibition
compared to 1st generation PCB technologies. However, they displayed a more favorable
vascular healing profile.
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Background: Juvenile domestic swine have been extensively used to test safety of
various antirestenotic therapies in peripheral arteries but it generally fails to provide
insights into efficacy. We investigated the potential of different combinations of balloon
or stent injury	treatment models in familial hypercholesterolemic (FH) swine to predict
the antirestenotic efficacy of drug-coated balloons.
Methods: Iliofemoral arteries of 32 FH swine were subjected to (1) denudation by a
Fogarty catheter immediately followed by DCB or Control (uncoated PTCA balloon)
treatment (De Novo Denudation	No Stent), (2) balloon overstretch and stent placement
immediately followed by the same DCB or Control treatment (De Novo
Overstretch	Stent), or (3) balloon overstretch and stent placement followed by the same
DCB or Control treatment 14-21 days later (In-Stent Restenosis). In all models, the net
neointimal proliferation was evaluated 28 days post-treatment by endovascular imaging
(IVUS or OCT).
Results: As expected, the neointimal response was much more robust in the De Novo
Overstretch	Stent than in the De Novo Denudation	No Stent model, but both De Novo
FH swine models failed to show the difference between DCB and Control. In contrast, 2
separate studies employing the In-Stent Restenosis model on the basis of FH swine,
demonstrated reduction of average stenosis by 50% by DCB in comparison to Control
(TABLE).
Conclusions: The peripheral in-stent restenosis model, in which neointimal proliferation
was induced by stent placement in iliofemoral arteries of FH swine and dilated 2-3 weeks
later by DCB or Control uncoated balloon, reliably differentiated the antirestenotic effect
of DCB from the Control effect in peripheral arteries. In contrast, either De Novo model
(of contemporaneous injury	treatment) developed in FH swine was not successful in that
regard.
Model
Imaging
Modality
Average Percent Area Stenosis
P value
Control
(Uncoated Balloon)
Drug-Coated
Balloon
De Novo
Denudation	No
Stent (n16)
IVUS 17.3 3.9% 19.0 4.7% 0.24
De Novo
Overstretch	Stent
(n11)
OCT 56.5 14.5% 43.8 13.4% 0.17
In-Stent Restenosis
(n16)
IVUS 58.3 11.6% 25.5 8.6% 0.001
In-Stent Restenosis
(n16)
OCT 47.0 13.0% 27.3 8.7% 0.003
TCT-593
Abstract Withdrawn
TCT-594
Efficacy and Safety of Drug-Eluting Balloon Compared to Drug-Eluting Stent
for The Treatment of In-Stent Restenosis (ISR)
Myung-Hyun Kim1, Byeong-Keuk Kim2
1Severance Hospital, Seoul, Korea, Republic of, 2Yonsei university, Seoul, Korea,
Republic of
Background: In recent studies, efficacy of drug-eluting balloon (DEB) angioplasty for
the treatment of coronary in-stent restenosis (ISR) was demonstrated. However there is
few data regarding efficacy and safety of DEB compared to drug-eluting stent (DES) in
treating ISR.
Methods: Initially we tried to evaluate the efficacy and safety of DEB for ISR. Instead
we compared the DEB data to other DES data prospectively obtained in our institution in
the same period. In this prospective registry from 2009 to 2010, 107 patients with ISR,
treated with a DEB (Paclitaxel-coated) (61 patients, 65 lesions) and DES (resolute
zotarolimus-eluting) (46 patients, 50 lesions) were included. Nine month angiographic
and 1 year clinical follow-up were completed for all patients. Dual antiplatelet agents were
administered for both groups at least 9 months. Safety endpoints were cardiac death,
myocardial infarction or stent thrombosis, and efficacy endpoints were more than 50% of
ISR and repeated target lesion revascularization (TLR) during follow-up.
Results: Baseline clinical and angiographic data did not significantly differ between two
groups. After 9 months TLR and ISR rates were significantly lower in DES group vs.
DEB group with 6.0% vs. 21.5% respectively (p0.02). Moreover, adverse cardiac events
(composite of cardiac death, myocardial infarction) occurred in DEB group (n2) while
there was no myocardial infarction in DES group.
Conclusions: Substituting DEB for DES as a repeated revascularization tool might not
be feasible in the maintenance of vascular patency in treating ISR.
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Background: In recent years, drug coated balloons have emerged as treatment option for
PCI. The present registry aims to evaluate the safety and efficacy of the Pantera Lux
Paclitaxel Coated Balloon in a real world setting.
Methods: Between April 2010 and April 2011, 1’064 patients were enrolled at 62 sites
in 12 countries. Clinical follow-up was performed at 1, 6 and 12 months. The primary
endpoint was MACE, a composite of all death, non-fatal MI and clinically driven TVR,
at 6 months. Secondary endpoints include MACE at 1 and 12 months. All reported MACE
were adjudicated by an independent clinical events committee.
Results: Seven hundred ninety-four men (74.6%) and 270 female (25.4%) with a mean
age of 66.5 10.7 yrs have been enrolled. Two hundred nineteen patients (20.6%)
presented with congestive heart failure, 362 patients (34.1%) were diabetics and 51.8%
(n551) had a history of previous MI. The majority of patients presented with stable
angina (n528, 49.6%) followed by unstable angina (n350, 32.9%). A total of 1’137
lesions were treated, mainly located in LAD (n436, 38.3%) and RCA (n410, 36.1%).
The mean reference vessel diameter was 2.8 mm and the mean target lesion length was
15.7 mm. Nine hundred ninety-seven lesions (87.7%) were in-stent restenotic (ISR)
lesions. Thereof 540 lesions were in a BMS (54.2%) and 448 lesions in a DES (44.9%).
The majority of ISR lesions were diffuse (n475, 49.0%, Mehran class II) or focal
(n316, 32.6%, Mehran class I). Follow-up compliance at 6 month follow up is 93.9%.
The MACE rate (hierarchical) at 6 months is 8.7% including 29 all death (2.9%, 19
cardiac death [1.9%]), 13 non-fatal MI (1.3%) and 44 clinically driven TVR (4.4%). In 32
cases (3.2%) a target lesion revascularization was needed. Twelve months MACE data
will be presented.
Conclusions: Treatment with the Pantera Lux Paclitaxel Coating Balloon showed
excellent acute and mid term performance in patients with mainly ISR lesions.
Efficacy and safety are demonstrated by low revascularization rates and low
non-fatal MI rate.
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